Lexicon Pharmaceuticals (LXRX) Common Equity (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Common Equity of $202.9 million for Q1 2026, up 64.88% year-over-year from $123.0 million in Q1 2025, and up 88.64% quarter-over-quarter from $107.5 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Common Equity (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Common Equity for 17 consecutive years, with $202.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 64.88% year-over-year to $202.9 million; the TTM figure through Mar 2026 stood at $202.9 million (up 64.88% YoY), while the FY2025 annual figure was $107.5 million, down 26.32% from the prior year.
- Common Equity improved to $202.9 million in Q1 2026 per LXRX's latest filing, from $107.5 million in the prior quarter.
- Across five years, Common Equity topped out at $288.9 million in Q1 2024 and bottomed at $70.8 million in Q2 2022.
- Historically, Common Equity has averaged $145.2 million across 5 years, with a median of $129.4 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity jumped 228.09% — and 2025, when it sank 57.41%.
- Lexicon Pharmaceuticals' Common Equity stood at $117.1 million in 2022, then slipped by 20.5% to $93.1 million in 2023, then soared by 56.75% to $146.0 million in 2024, then slipped by 26.32% to $107.5 million in 2025, then surged by 88.64% to $202.9 million in 2026.
- Business Quant data shows LXRX's Common Equity at $202.9 million in Q1 2026, $107.5 million in Q4 2025, and $120.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 174.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 174.53 Mn |
| Mar 31, 2026 | 202.86 Mn |
| Dec 31, 2025 | 107.54 Mn |
| Sep 30, 2025 | 120.16 Mn |
| Jun 30, 2025 | 129.44 Mn |
| Mar 31, 2025 | 123.03 Mn |
| Dec 31, 2024 | 145.95 Mn |
| Sep 30, 2024 | 178.51 Mn |
| Jun 30, 2024 | 239.98 Mn |
| Mar 31, 2024 | 288.87 Mn |
| Dec 31, 2023 | 93.11 Mn |
| Sep 30, 2023 | 139.51 Mn |
| Jun 30, 2023 | 186.36 Mn |
| Mar 31, 2023 | 88.05 Mn |
| Dec 31, 2022 | 117.12 Mn |
| Sep 30, 2022 | 144.02 Mn |
| Jun 30, 2022 | 70.83 Mn |
| Mar 31, 2022 | 92.70 Mn |
| Dec 31, 2021 | 113.60 Mn |
| Sep 30, 2021 | 136.60 Mn |